IGEA Pharma N.V. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was EUR 0.0057 million compared to EUR 0.0182 million a year ago. Net loss was EUR 0.2123 million compared to EUR 0.7187 million a year ago.

Basic loss per share from continuing operations was EUR 0.001 compared to EUR 0.002 a year ago. Diluted loss per share from continuing operations was EUR 0.001 compared to EUR 0.002 a year ago.